Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical, Inc. (ICUI) delivers innovative infusion therapy solutions that enhance patient safety across healthcare settings. This news hub provides investors and medical professionals with timely updates on corporate developments, regulatory milestones, and clinical advancements shaping the future of drug delivery systems.
Access official press releases covering new product approvals, strategic acquisitions, and financial performance alongside analysis of market trends impacting the infusion devices sector. Our curated collection simplifies tracking ICUI's progress in developing closed-system transfer devices and smart infusion technologies that reduce healthcare-associated infections.
Discover updates on ICUI's expanding portfolio of medical consumables and monitoring systems used in critical care environments. Content spans FDA clearances, partnership announcements, and clinical study results demonstrating product efficacy. The resource serves as a comprehensive reference for understanding the company's role in advancing IV safety standards globally.
Bookmark this page for streamlined access to ICU Medical's latest developments in smart pump technology and hazardous drug handling solutions. Check regularly for verified updates about operational expansions and quality initiatives maintaining ICUI's position as an infusion therapy market leader.
ICU Medical and Otsuka Pharmaceutical Factory have announced a joint venture aimed at strengthening IV solutions manufacturing and innovation in North America. This partnership will create one of the largest global IV solutions manufacturing networks, producing an estimated 1.4 billion units annually. The joint venture will combine OPF's global manufacturing scale with ICU Medical's strong North American production and distribution capabilities, enhancing supply chain resiliency and accelerating new product development. ICU Medical will provide commercial services to ensure seamless operations. The venture is expected to become operational in early Q2 2025. Key economic terms include a $200 million upfront payment from OPF to ICU Medical, performance-based milestones by the end of 2026, and a put-call option in 2030 and beyond. This collaboration aims to address persistent supply chain challenges in the North American IV solutions market and deliver clinical and economic value to customers.
ICU Medical (ICUI) has announced its participation in the UBS Global Healthcare Conference in Rancho Palos Verdes, California, scheduled for November 11-14, 2024. The company's presentation is set for Wednesday, November 13, 2024, at 4:15 p.m. PT (7:15 p.m. ET). Management will also conduct one-on-one meetings on the same day. Investors and interested parties can access the live webcast through ICU Medical's website under the Investors and Event Calendar tabs, with replay options available.
ICU Medical (Nasdaq: ICUI) has scheduled its third quarter 2024 earnings release and conference call for Tuesday, November 12th, 2024. The company will release results at approximately 4:00 p.m. ET and host a conference call at 4:30 p.m. ET. Investors can access the call via phone at (800) 343-5172 using conference ID 'ICUMED' or through a webcast on the company's website. A replay of the webcast will be available afterward.
ICU Medical (Nasdaq:ICUI), a leading innovator in medical product development and manufacturing, has announced its participation in two major investor conferences this September. The company's CEO, Vivek Jain, will be attending:
1. The Wells Fargo 2024 Healthcare Conference in Boston on September 4, where he will engage in one-on-one meetings.
2. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 6, featuring a fireside chat at 4:00 a.m. PT (7:00 a.m. ET). This discussion will be webcast live on ICU Medical's Investor Relations website and archived for future viewing.
These events provide valuable opportunities for investors to gain insights into ICU Medical's operations and future plans.
ICU Medical (Nasdaq:ICUI) reported its Q2 2024 financial results. Revenue increased to $596.5 million, up from $549.3 million in Q2 2023. GAAP gross profit rose to $207.4 million, with a gross margin of 35%. However, the company reported a GAAP net loss of $(21.4) million, or $(0.88) per diluted share, compared to a loss of $(9.9) million in Q2 2023. Adjusted diluted EPS was $1.56, down from $1.88 in the previous year. Adjusted EBITDA decreased to $91.3 million from $98.1 million.
The company updated its fiscal year 2024 guidance, narrowing the range for adjusted EBITDA to $345-$365 million and increasing the range for diluted EPS to $4.95-$5.35. Revenue growth was observed across all product lines, with Consumables showing the largest increase.
ICU Medical (Nasdaq: ICUI), a leading innovator in medical product development and manufacturing, has announced its schedule for the second quarter 2024 earnings release and conference call. The company will disclose its Q2 2024 results on Wednesday, August 7th, 2024, at approximately 4:00 p.m. ET. Following this, a conference call will be held at 4:30 p.m. ET on the same day to discuss the results.
Interested parties can access the call by dialing (800) 579-2543 and using the conference ID "ICUMED". Additionally, a simultaneous webcast will be available on the company's website at www.icumed.com. To access the webcast, navigate to the Investors tab and click on the Webcast icon. The webcast will also be available for replay after the live event.
ICU Medical, Inc. announced its First Quarter 2024 Results with revenue of $566.7 million, a slight decrease from the previous year. The GAAP gross profit was $185.2 million, with a net loss of $(39.5) million. Adjusted diluted earnings per share were $0.96, and Adjusted EBITDA was $78.8 million. Revenues by product line showed fluctuations, with Vital Care including revenue from a Pfizer contract. CEO Vivek Jain stated that the results were as expected.
FAQ
What is the current stock price of Icu Medical (ICUI)?
What is the market cap of Icu Medical (ICUI)?
